MK0653, ezetimibe + Comparator: placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
72
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lipid Metabolism, Inborn Errors

Conditions

Lipid Metabolism, Inborn Errors, Heart Disease

Trial Timeline

Oct 1, 2004 โ†’ Oct 1, 2005

About MK0653, ezetimibe + Comparator: placebo

MK0653, ezetimibe + Comparator: placebo is a phase 3 stage product being developed by Organon for Lipid Metabolism, Inborn Errors. The current trial status is completed. This product is registered under clinical trial identifier NCT00092898. Target conditions include Lipid Metabolism, Inborn Errors, Heart Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT00092898Phase 3Completed
NCT00092807Phase 3Completed
NCT00092820Phase 3Completed

Competing Products

20 competing products in Lipid Metabolism, Inborn Errors

See all competitors